<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04057118</url>
  </required_header>
  <id_info>
    <org_study_id>OSCO-P2201</org_study_id>
    <nct_id>NCT04057118</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Effectiveness and Safety of SKI-O-703 in Patients Experiencing Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies.</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Dose Study to Evaluate the Efficacy and Safety of Oral SKI-O-703 in Patients With Active Rheumatoid Arthritis Despite Treatment With Conventional Therapies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oscotec Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oscotec Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the safety and efficacy of SKI-O-703 compared with placebo, in&#xD;
      patients with active rheumatoid arthritis (RA) who have had an inadequate response to&#xD;
      conventional synthetic disease-modifying agents. Patients will be randomly assigned to one of&#xD;
      4 groups and will receive one of three doses of SKI-O-703 or placebo, administered orally&#xD;
      twice daily for 12 weeks.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">March 20, 2019</start_date>
  <completion_date type="Anticipated">October 2020</completion_date>
  <primary_completion_date type="Anticipated">October 2020</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in disease activity score</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean change from baseline in disease activity score for 28 joints (DAS28) using hsCRP (high sensitivity C-reactive protein)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>• Percentage of patients with ACR20 (American College of Rheumatology 20) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>ACR20 score is the percentage of patients showing ≥20% improvement from baseline in tender joint count (68 joint counts), ≥20% improvement in swollen joint count (66 joint counts), and ≥20% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of patients with ACR50 (American College of Rheumatology 50) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>ACR50 score is the percentage of patients showing ≥50% improvement from baseline in tender joint count (68 joint counts), ≥50% improvement in swollen joint count (66 joint counts), and ≥50% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>• Percentage of patients with ACR70 (American College of Rheumatology 70) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>ACR70 score is the percentage of patients showing ≥70% improvement from baseline in tender joint count (68 joint counts), ≥70% improvement in swollen joint count (66 joint counts), and ≥70% improvement in at least 3 of the following: patient's global assessment of arthritis pain; patient's global assessment of disease activity; physician's global assessment of disease activity; health assessment questionnaire-disability index (HAQ-DI); hsCRP (high sensitivity C-reactive protein)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Health Assessment Questionnaire-Disability Index (HAQ-DI) score</measure>
    <time_frame>Baseline and Weeks 2, 4 8 and 12</time_frame>
    <description>Change from baseline measured by disability index</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious Adverse Events (SAEs)</measure>
    <time_frame>Up to Week 16</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">148</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SKI-O-703</intervention_name>
    <description>Oral administration, twice per day</description>
    <arm_group_label>SKI-O-703 100 mg</arm_group_label>
    <arm_group_label>SKI-O-703 200 mg</arm_group_label>
    <arm_group_label>SKI-O-703 400 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral administration, twice per day</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients must provide written, signed, informed consent.&#xD;
&#xD;
          -  Patients must have a diagnosis of Rheumatoid Arthritis (RA) according to American&#xD;
             College of Rheumatology (ACR) criteria or the 2010 ACR/European League Against&#xD;
             Rheumatism classification, for at least 6 months prior to first administration of&#xD;
             study drug.&#xD;
&#xD;
          -  Patients must have active RA at screening and baseline (Day 1 of the study).&#xD;
&#xD;
          -  Patients who have active disease despite csDMARD (conventional synthetic&#xD;
             disease-modifying antirheumatic drugs) therapy for at least 3 months prior to Day 1 of&#xD;
             the study.&#xD;
&#xD;
          -  Patients must have had an inadequate response to previous anti-TNF⍺ (anti-tumor&#xD;
             necrosis factor alpha) biological agent(s) for the treatment of RA and meet the&#xD;
             washout period prior to Day 1 of the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients receiving oral agents, except for medications listed in inclusion criteria&#xD;
             for the treatment of RA.&#xD;
&#xD;
          -  Patients who have previously received any other or biological agent for the treatment&#xD;
             of RA, other than anti-TNF⍺ inhibitor(s).&#xD;
&#xD;
          -  Patients who have a current or past history of hepatitis B virus (HBV) infection;&#xD;
             positive test for hepatitis C virus (HCV) antibody; positive test for human&#xD;
             immunodeficiency virus (HIV); history of or concurrent interstitial pneumonia; acute&#xD;
             infection requiring oral antibiotics within 2 weeks, or parenteral injection of&#xD;
             antibiotics within 4 weeks prior to first administration of the study drug; other&#xD;
             serious infection within 6 months prior to first administration of study drug;&#xD;
             recurrent herpes zoster or other chronic or recurrent infection within 6 weeks prior&#xD;
             to first administration of the study drug; past or current granulomatous infections or&#xD;
             other severe or chronic infection; positive test for tuberculosis (TB) or other&#xD;
             evidence of TB.&#xD;
&#xD;
          -  Patients with uncontrolled diabetes mellitus, or uncontrolled hypertension (systolic&#xD;
             blood pressure ≥160 mm Hg or diastolic blood pressure ≥100 mm Hg).&#xD;
&#xD;
          -  Patients with any other inflammatory or rheumatic diseases that could impact the&#xD;
             evaluation of the effect of the study drug.&#xD;
&#xD;
          -  Patients with a history of malignancy within 5 years prior to first administration of&#xD;
             the study drug, except completely excised and cured squamous cell carcinoma, carcinoma&#xD;
             of the cervix in situ, cutaneous basal cell carcinoma, or cutaneous squamous cell&#xD;
             carcinoma.&#xD;
&#xD;
          -  New York Heart Association (NYHA) class III or IV heart failure, severe uncontrolled&#xD;
             cardiac disease or heart attack within 6 months prior to first administration of the&#xD;
             study drug.&#xD;
&#xD;
          -  Female patients who are currently pregnant, breastfeeding or planning to become&#xD;
             pregnant or breastfeed within 6 months of the last dose of the study drug.&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria could apply.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3110)</name>
      <address>
        <city>Beverly Hills</city>
        <state>California</state>
        <zip>90211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3105)</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational (Site 3104)</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>33014</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3112)</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3108)</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40504</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3102)</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <zip>73103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3107)</name>
      <address>
        <city>Duncansville</city>
        <state>Pennsylvania</state>
        <zip>16635</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (3106)</name>
      <address>
        <city>Carrollton</city>
        <state>Texas</state>
        <zip>75010</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3111)</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3109)</name>
      <address>
        <city>Mesquite</city>
        <state>Texas</state>
        <zip>75150</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3103)</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 3101)</name>
      <address>
        <city>Tomball</city>
        <state>Texas</state>
        <zip>77375</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2101)</name>
      <address>
        <city>Ostrava</city>
        <zip>702 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2102)</name>
      <address>
        <city>Zlín</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2208)</name>
      <address>
        <city>Wrocław</city>
        <state>Dolnoslaskie</state>
        <zip>53-224</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2204)</name>
      <address>
        <city>Bydgoszcz</city>
        <state>Kujawsko-pomorskie</state>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2207)</name>
      <address>
        <city>Lublin</city>
        <state>Lubelskie</state>
        <zip>20-582</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2202)</name>
      <address>
        <city>Warszawa</city>
        <state>Mazowieckie</state>
        <zip>01-518</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2201)</name>
      <address>
        <city>Białystok</city>
        <state>Podlaskie</state>
        <zip>15-879</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2209)</name>
      <address>
        <city>Ostrowiec Świętokrzyski</city>
        <state>Swietokrzyskie</state>
        <zip>27-400</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2203)</name>
      <address>
        <city>Poznań</city>
        <state>Wielkopolskie</state>
        <zip>61-397</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2206)</name>
      <address>
        <city>Nadarzyn</city>
        <zip>05-830</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2307)</name>
      <address>
        <city>Kemerovo</city>
        <zip>650066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2304)</name>
      <address>
        <city>Moscow</city>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2305)</name>
      <address>
        <city>Moscow</city>
        <zip>129110</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2308)</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2306)</name>
      <address>
        <city>Ryazan'</city>
        <zip>390026</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2302)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>194291</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2303)</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2301)</name>
      <address>
        <city>Tomsk</city>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2510)</name>
      <address>
        <city>Ivano-Frankivs'k</city>
        <state>Ivano-Frankivs'ka Oblast</state>
        <zip>76018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2505)</name>
      <address>
        <city>Ternopil'</city>
        <state>Ternopil's'ka Oblast'</state>
        <zip>46002</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2506)</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21018</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2504)</name>
      <address>
        <city>Vinnytsia</city>
        <state>Vinnyts'ka Oblast'</state>
        <zip>21029</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2508)</name>
      <address>
        <city>Kharkiv</city>
        <zip>61058</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2501)</name>
      <address>
        <city>Kyiv</city>
        <zip>01023</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2503)</name>
      <address>
        <city>Kyiv</city>
        <zip>04050</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2502)</name>
      <address>
        <city>Kyiv</city>
        <zip>4107</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2507)</name>
      <address>
        <city>Poltava</city>
        <zip>36024</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oscotec Investigational Site (Site 2509)</name>
      <address>
        <city>Vinnytsia</city>
        <zip>21009</zip>
        <country>Ukraine</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czechia</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Ukraine</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>August 13, 2019</study_first_submitted>
  <study_first_submitted_qc>August 13, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 15, 2019</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

